Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.

Sponsor and Collaborators
Assistance Publique – Hôpitaux de Paris

Contact
Contact: Zakia Idir, PhD
+33 1 4484 1747
[email protected]

Continue Reading

Principal Investigator
Celeste Lebbe, MD, PhD Hôpital Saint-Louis, Paris, France

ClinicalTrials.gov Identifier
NCT01168050